Pharmaceutical Therapies for Necroptosis in Myocardial Ischemia-Reperfusion Injury

Area of Science:

• Cardiovascular Biology
• Cell Death Mechanisms
• Molecular Medicine

Background:

• Cardiovascular disease burden is rising globally, driven by aging, diabetes, and obesity.
• Myocardial ischemia-reperfusion injury (MI-RI) is a major cause of cardiovascular morbidity and mortality.
• Necroptosis plays a critical role in MI-RI, but its precise molecular mechanisms and interactions with other pathways require further elucidation.

Purpose of the Study:

• To review the molecular mechanisms of necroptosis in the context of MI-RI.
• To explore the interplay between necroptosis and other cell death/signaling pathways (autophagy, ferroptosis, CaMKII, NF-κB, JNK-Bnip3).
• To summarize recent advancements in pharmaceutical strategies targeting necroptosis for cardioprotection.

Main Methods:

• Literature review of studies on necroptosis, MI-RI, and related signaling pathways.
• Analysis of molecular mechanisms involving RIPK1, RIPK3, MLKL, and their upstream/downstream effectors.
• Synthesis of findings on the therapeutic potential of necroptosis inhibitors.

Main Results:

• Necroptosis, regulated by RIPK1/RIPK3/MLKL, is a key contributor to MI-RI.
• MI-RI involves a complex interplay of necroptosis with autophagy, ferroptosis, and signaling cascades like CaMKII and NF-κB.
• Inhibitors targeting necroptosis have demonstrated efficacy in reducing myocardial inflammation, infarct size, and improving cardiac function in preclinical models.

Conclusions:

• Necroptosis is a critical therapeutic target for mitigating MI-RI.
• Understanding the crosstalk between necroptosis and other pathways is essential for developing effective cardioprotective strategies.
• Targeted inhibition of necroptosis offers a promising avenue for novel pharmaceutical interventions against cardiovascular disease.